Metagenomi, Inc. Common Stock (MGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has a cash flow conversion efficiency ratio of -0.154x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.18 Million) by net assets ($137.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MGX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Metagenomi, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Metagenomi, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Metagenomi, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Moorim Paper
KO:009200
|
-0.006x |
|
GenMont Biotech Inc
TW:3164
|
0.034x |
|
Liberty Shoes Limited
NSE:LIBERTSHOE
|
0.117x |
|
Investment and Trading of Real Estate JSC
VN:ITC
|
N/A |
|
MBL Infrastructure Limited
NSE:MBLINFRA
|
0.003x |
|
Leading Edge Materials Corp
V:LEM
|
-0.032x |
|
EPE Capital Partners Ltd
JSE:EPE
|
-0.059x |
|
PASSUS S.A. ZY-1
F:71X
|
0.078x |
Annual Cash Flow Conversion Efficiency for Metagenomi, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Metagenomi, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Metagenomi, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $158.60 Million | $-88.89 Million | -0.560x | -20.69% |
| 2024-09-30 | $234.86 Million | $-109.07 Million | -0.464x | -9.32% |
| 2023-09-30 | $215.17 Million | $-91.41 Million | -0.425x | -6.37% |
| 2022-09-30 | $-74.43 Million | $29.72 Million | -0.399x | +46.42% |
| 2021-09-30 | $-32.54 Million | $24.26 Million | -0.745x | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more